Full Press Release Details
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON--(BUSINESS WIRE)--Aug. 31, 2026--Seaport Therapeutics, Inc.(Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences:
• 21stAnnualWells Fargo Healthcare ConferenceSeptember 8–10, 2026Seaport will participate in one-on-one investor meetings
• September 8–10, 2026
• Seaport will participate in one-on-one investor meetings
• Citi’s 2026 Biopharma Back toSchool ConferenceSeptember 9–10, 2026Fireside chat:September 9, 2026at1:00 p.m. ETSeaport will participate in one-on-one investor meetings
• September 9–10, 2026
• Fireside chat:September 9, 2026at1:00 p.m. ET
• Seaport will participate in one-on-one investor meetings
A live webcast of the Citi fireside chat will be available on the Investors section of the Company’s website athttps://investors.seaporttx.com/news-events/events. An archived replay will be available following the presentation.
About Seaport Therapeutics
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary GlyphTMplatform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visitwww.seaporttx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260831442211/en/
Seaport TherapeuticsMedia Contact:Shannon CostelloVice President, Communicationspublicrelations@seaporttx.comInvestor Contact:Adam Bero, Ph.D.Head of Investor Relationsir@seaporttx.com
Source: Seaport Therapeutics, Inc.